Promomed has developed an injectable form of Areplivir for hospitalized COVID-19 patients

PROMOMED Group of Companies is launching clinical trials of an injectable form of Areplivir for the treatment of coronavirus infection. The Ministry of Health of the Russian Federation has granted permission to conduct Phase I clinical trials.

A safety study of the drug, produced as a lyophilizate for the preparation of infusion solutions, will be conducted at the State Budgetary Healthcare Institution of the Yaroslavl Region Clinical Hospital No. 3 and will last until the end of September 2021.

After completing all stages of clinical trials, Russian doctors will receive an effective drug for the treatment of hospitalized COVID-19 patients, including those with severe illness. Peter Bely, Chairman of the Board of Directors of Promomed Group, noted: "We continue scientific research in the field of creating innovative effective and safe medicines to fight infections. At the same time, we are expanding and modernizing the capacities of the Biochemik plant in order to consistently and with guaranteed quality provide domestic healthcare with vital medicines, including those aimed at treating the new coronavirus infection COVID-19."

Today, Areplivir (INN: favipiravir) is available in the form of tablets of 40 pcs. in one package. According to Dmitry Pushkar, a member of the consortium of the academic community for the study of coronavirus infection, Academician of the Russian Academy of Sciences, etiotropic therapy occupies an important place in the treatment of COVID-19. "Favipiravir is recommended by the Ministry of Health of the Russian Federation for the treatment of coronavirus infection of any severity. International data on the effectiveness of the combined use of favipiravir with monoclonal antibodies are emerging. If we talk about hospitalized patients, and these are most often patients with a severe course, then the injectable form of favipiravir will, on the one hand, be more convenient to use, on the other, it may increase the effectiveness of therapy," he said.

Areplivir is a drug with targeted action against RNA-containing viruses, which include SARS-Cov-2. In the course of clinical trials conducted in 2020 under the guidance of full members of the Russian Academy of Sciences in 5 Russian medical institutions, it has proven to be highly effective in treating the new coronavirus infection (ensuring the elimination of the virus from the body, improving lung condition, reducing the risks of severe course and accelerating recovery).

It is part of the priority treatment regimen in the methodological recommendations of the Ministry of Health for the treatment of COVID-19. It is included in the list of vital and essential medicines.